2015, № 12 (187)

Drozdova E.A., Khokhlova D.Yu. EFFECT OF ANTIHYPERTENSIVE MEDICINES ON THE EFFICACY OF INTRAVITREAL RANIBIZUMAB IN PATIENTS WITH RETINAL VEIN OCCLUSIONThe article is devoted to an actual problem in ophthalmology — treatment of macular edema due to retinal vein occlusion (RVO). Systemic hypertension (SH) is one of systemic risk factors of RVO, and treatment of SH is carried out by different groups of medicines. Purpose: to determine the effect of antihypertensive medicines on the efficacy of intravitreal injection (IVI) of ranibizumab in patients with RVO. We investigated 48 patients with RVO, performed standard and modern methods examination, made of (IVI) ranibizumab according to standard. All patients had SH. 25 patients (52 %) had compensation of SH. Of all patients 16 patients (33 %) took for treatment of SH angiotensin converting enzyme inhibitors (ACE inhibitors), 9 (19 %) — β-blockers and calcium channel blockers. 23 patients (48 %) had decompensation of SH. Mean best-corrected visual acuity increased in patients with compensation blood pressure of ACE inhibitors: 0.5 ± 0.1 in group with nonischemic type and 0.12 ± 0.1 in group with ischemic type, and decrease of macular edema. ACE inhibitors increases the efficacy of IVI ranibizumab. The decompensation of SH may worsen the prognosis of visual functions, which need to be considered prior to IVI of ranibizumab.Key words: retinal vein occlusion, macular edema, ranibizumab, angiotensin-converting enzyme inhibitors.

Download

References:

1. Drozdova, E.A. Efficacy of intravitreal ranibizumab for the treatment of macular edema associated with retinal vein occlusion depending on the compensation of systemic risk factors / E.A. Drozdova, D. Yu. Khokhlova // Russian Ophthalmological Journal. — 2015. — Vol.8. — №2. — P. 21-25.

2. Tultseva, S.N. The role of inflammation in the pathogenesis of macular edema. Modern trends of medical treatment / S.N. Tultseva, Yu. S. Astakhov // Ophthalmologic vedomosti. — 2012. — Vol. V. — №4. — P. 35-44.

3. Brown, D.M. CRUISE Investigators Ranibizumab for macular edema following central retinal vein occlusion: six month primary end point results of phase III study / D.M. Brown, P.A. Campochiaro, R.P. Singh, Li Z, S. Gray, N. Saroj, A.C. Rundle, R.G. Rubio, W.Y. Murahashi // Ophthalmology. — 2010. — Vol. 117(6). — P. 1124-1133.

4. Campochiaro, P.A. BRAVO Investigators Ranibizumab for macular edema following branch retinal vein occlusion: six month primary end point results of phase III study / P.A. Campochiaro, J.S. Heier, L. Feiner, S. Gray, N. Saroj, A.C. Rundle, W.Y. Murahashi, R.G. Rubio // Ophthalmology. — 2010. — Vol. 117(6). — P. 1102-1112.

5. Coscas, G. Macular edema a practical approach / G. Coscas, J. Cunha-Vaz, A. Loewenstein // Developments in ophthalmology. — 2010. — Vol. 47. — P. 34.

6. ESH/ESC 2013 Guidelines for the management of arterial hypertension // Journal of Hypertension. — 2013. — Vol. 31 (7). — P. 1281–1357.

7. Heier, S. Ranibizumab for macular edema due to retinal vein occlusions / S. Heier, P. Campochiaro et al. // Ophthalmology. — 2012. — P.802-809.

8. Higashi, Y. Endothelial function and oxidative stress in cardiovascular diseases / Y. Higashi, K. Noma, M. Yoshizumi et al. // Circulation Journal. — 2009. — Vol. 3. — Р. 411-415.

9. Karia, N. Retinal vein occlusion: pathophysiology and treatment options / Clin. Ophthalmol. — 2010. — №4. — Р. 809–816.

10. Keane, P. Retinal vein occlusion and macular edema — critical evaluation of the clinical value of ranibizumab / P. Keane, R. Sadda // Clinical Ophthalmology. — 2011. — P. 771–781.

11. Kida, T. Treatment of systemic hypertention is important for improvement of macular edema associated with retinal vein occlusions / T. Kida, S. Morishita // Clinical Ophthalmology. — 2014. — P. 955-958.

12. Martнnez, F. Risk factors associated with retinal vein occlusion / F. Martinez, E. Furio, M. J. Fabia, A. V. International Journal of Clinical Practice. — 2014. — Vol. 68(7). — Р. 871-881.

13. Muraoka, Y. Morphologic and functional changes in retinal vessels associated with branch retinal vein occlusion / Y. Muraoka, A. Tsujikawa, T. Murakami // Ophthalmology. — 2012. — Vol. 120. — P. 91–99.

14. Pieramici, D.J. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions / D.J. Pieramici, M. Rabena, A.A. Castellatin et al. // Ophthalmology. — 2008. — Vol. 115 (10). — P.47-54.

15. Stefansson, E. Treatment of branch retinal vein occlusion / Е. Stefansson // ActaOphthalmol. — 2008. — Vol. 86, №1. — P. 122–123.

16. Stem, M.S. A longitudinal analysis of risk factors associated with central retinal vein occlusion / M.S. Stem, N. Talwar, G.M. Comer, J.D. Stein // Ophthalmology. — 2013. — Vol. 120(2). — P. 362-370.

About this article

Authors: Hohlova D.Yu., Drozdova E.A.

Year: 2015

Editor-in-chief

Sergey Aleksandrovich
MIROSHNIKOV

© Электронное периодическое издание: ВЕСТНИК ОГУ on-line (VESTNIK OSU on-line), ISSN on-line 1814-6465
Зарегистрировано в Федеральной службе по надзору в сфере связи, информационных технологий и массовых коммуникаций
Свидетельство о регистрации СМИ: Эл № ФС77-37678 от 29 сентября 2009 г.
Учредитель: Оренбургский государственный университет (ОГУ)
Главный редактор: С.А. Мирошников
Адрес редакции: 460018, г. Оренбург, проспект Победы, д. 13, к. 2335
Тел./факс: (3532)37-27-78 E-mail: vestnik@mail.osu.ru